Testing Claseprubart for Generalized Myasthenia Gravis
Treatments studied
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This study tests whether a new drug called claseprubart can help adults with generalized myasthenia gravis (a condition where muscles get weak and tired easily). The drug works by targeting part of the immune system that damages muscles.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have generalized myasthenia gravis confirmed by blood tests and nerve/muscle testing
- Your myasthenia gravis is moderate to moderately severe (MGFA Class II–IVa)
- You weigh between 88 and 286 pounds (40–130 kg)
- You have received vaccinations against certain bacterial infections
- You agree not to become pregnant or father a child during the study and use effective birth control if sexually active
- You have not had thymic surgery, a thymoma, or cancer in the past 5 years (except certain skin cancers)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called aritinercept to see if it can help people with generalized myasthenia gravis (a condition where muscles weaken over time). Researchers believe this drug may reduce the immune system activity that causes muscle weakness.
This study tests a new medication called povetacicept for people with generalized myasthenia gravis. The goal is to see if it can reduce muscle weakness and improve daily functioning.
This trial tests whether tocilizumab can improve symptoms and safety in people with generalized myasthenia gravis (MG) who already take standard MG treatments. It may help if your weakness is still significant despite current therapy.
This trial tests multiple treatment combinations for people with myasthenia gravis (MG), a condition that causes muscle weakness. It aims to find safer and more effective options by comparing different therapies.
This study adds a new drug called empasiprubart to the existing treatment efgartigimod for people with generalized myasthenia gravis (gMG) who have antibodies against acetylcholine receptors (AChR-Ab) and have only partially responded to efgartigimod. The goal is to see if the combination improves daily living more than efgartigimod alone.
This trial tests an experimental oral medication called NMD670 for people with myasthenia gravis (MG). It aims to see if the drug is safe and if it helps improve muscle strength and daily function.
Hear when a new Myasthenia Gravis, Generalized trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.